Key points are not available for this paper at this time.
iMRS provides personalized immunotherapy prediction for LUAD patients. SLC25A1, identified as a novel immune-exclusion related oncogene, represents a promising therapeutic target for LUAD treatment.
Pengpeng et al. (Wed,) studied this question.